• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

High-Titer Convalescent Plasma Increases Long-Term Survival for Patients with Severe COVID-19

November 16, 2022

Randomized controlled clinical trials have evaluated the safety and efficacy of COVID-19 convalescent plasma (CCP) and found high-titer CCP reduced the risk of hospitalization if used early in the course of disease.  However, little is known about the long-term effect of CCP.  Fifty hospitalized patients (74% male; median age 58.5 years) with severe COVID-19 in the CASPID randomized clinical trial were followed for a median time of 396 days; 16 received high-titer CCP, 14 received low-titer CCP, and 20 received standard care.  In addition, 113 CCP donors (52% male; median age 42.0 years) were followed for a median of 519 days.  The one-year survival of patients in the high-titer CCP study arm (n=16) was 91.5%, which was significantly higher than patients in the low-titer arm (n=14; 67.4% survival) and the control arm (n=20; 60.2% survival).  Furthermore, patients treated with the high-titer CCP had a significantly shorter stay in the ICU and hospital compared to patients in the low-titer and control groups. The study also found that hospitalized patients with severe COVID-19 had a lower quality of life compared to CCP donors.  Larger studies are needed to confirm this observation and the long-term benefits of CCP.

Reference:

Körper S, Grüner B, Zickler D, Wiesmann T, et al.  One-year follow-up of the CASPID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.  Journal of Clinical Investigation 2022

Filed Under

  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Daprodustat is Noninferior to Erythropoiesis-Stimulating Agents for Patients with Chronic Kidney Disease Undergoing Dialysis

  • COVID-19 Convalescent Plasma Provides More than Neutralizing Antibodies

  • Serosurveillance of SARS-CoV-2 from Blood Donations across the U.S.

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley